Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hafnia Limited Common Shares (HAFN) vs Illumina, Inc. (ILMN) Price & Performance

Hafnia Limited Common SharesTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Hafnia Limited Common Shares vs Illumina, Inc. — how do they compare? Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B), while Illumina, Inc. trades at $271.84 (market cap $40.95B). The key difference: Illumina, Inc. is far larger — about 7.1× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Illumina, Inc. for 84 Days on average.

HAFNILMN
Market Cap
$5.76B$40.95B
Volume
1,835,7251,893,606
Sector
IndustrialsHealth
52-Week High
$10.92$293.69
52-Week Low
$5.21$93.00
Typical Hold Time
0 Days84 Days
Enterprise Value
$6.37B$42.31B
Dividend Yield
10.24%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hafnia Limited Common Shares

HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.

Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.

Illumina, Inc.

Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.

ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HAFN
100% Buy0% Sell
Avg holding period · 0 Days
ILMN

No sentiment data available yet.

Top news

Latest headlines on both assets

About Hafnia Limited Common Shares

Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.

Read more on HAFN →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →